Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Development pipeline by Year
Development pipeline — Total active mRNA development programs (programs)
Moderna Development pipeline: 35.00 programs in FY2025, down 20.5% from a year earlier.
Latest, FY2025
35.00
Period ended Dec 31, 2025
Change on a year earlier
-20.5%
44.00 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Note 1 (Description of Business) & MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development pipeline — Total active mRNA development programs (programs) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.00 | -20.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 44.00 | -2.2% | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | 45.00 | -6.2% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 48.00 | +9.1% | FY2022 10-K ↗ |
| FY2021 | Dec 31, 2021 | 44.00 | +83.3% | FY2021 10-K ↗ |
| FY2020 | Dec 31, 2020 | 24.00 | +4.3% | FY2020 10-K ↗ |
| FY2019 | Dec 31, 2019 | 23.00 | +15.0% | FY2019 10-K ↗ |
| FY2018 | Dec 31, 2018 | 20.00 | – | FY2018 10-K ↗ |
Breakdown
What makes up development pipeline
Cite this data
StockData. (2026). Moderna Development pipeline, annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/pipeline-programs
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.